Cognitive Enhancers in Alzheimer's Disease

References

• Alzheimer A. “Uber eine eigenartige Erkankung der Hirnrinde.”. Allg A Psychiatrie 1970; 64: 1460–1480
   Google Scholar
• Constantinides J. “Is Alzheimer's disease a major form of senile dementia? Clinical, anatomical, and genetic data,”. Alzheimer's Disease: Senile Dementia and Related Disorders, R Katzman, R D Terry, K L Bick. Raven Press, New York 1978; Vol 7: 15–25
   Google Scholar
• Roth M. Diagnosis of senile and related forms of dementia. Alzheimer's Disease: Senile Dementia and Related Disorders, R Katzman, R D Terry, K L Bick. Raven Press, New York 1978; Vol 7: 71–85
   Google Scholar
• Petrie W M, Ban T A. Drugs in geropsychiatry. Psychopharmacol Bull 1978; 14: 7–19
   PubMedGoogle Scholar
• Salzman C. Stimulants in the elderly. Age and the Pharmacology of Psychoactive Drugs, A Raskin, D S Rovinson, J Levine. Elsevier North Holland Inc., New York 1981; 171–180
   Google Scholar
• Reding M J, Young R, Di Ponte P. Amitriptyline in Alzheimer's disease. Neurology 1983; 33: 522–523
   PubMedGoogle Scholar
• Cutler N R, Narang P K. Implications of dosing tricyclic antidepressants and benzodiazepines in geriatrics. Psychiatr Clin North Am 1984; 7: 1–17
   PubMed Web of Science ®Google Scholar
• Hollister L E, Yesavage J. Ergoloid mesylates for senile dementias: Unanswered questions. Ann Intern Med 1984; 100: 894–989
   PubMed Web of Science ®Google Scholar
• Van Loveren-Huyben C MS, Engelaan H FW, Hermans M BM, Van der Bom J A, Leering C, Munnichs J MA. Double-blind clinical and psychologic study of ergoloid mesylates (Hydergine) in subjects with senile mental deterioration. J Am Geriatr Soc 1984; 32: 584–588
   PubMed Web of Science ®Google Scholar
• Epstein L J. Anxiolytics, antidepressants, and neuroleptic patients. Psychopharmacology: A Generation of Progress, M A Lipton, A DiMascio, K F Killam. Raven Press, New York 1978; 1517–1523
   Google Scholar
• Coyle J T, Price D L, De Long M R. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983; 219: 1184–1190
   PubMed Web of Science ®Google Scholar
• Terry R D, Peck A, Deteresa R, Schechter R, Horoupian D S. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981; 10: 184–192
   PubMed Web of Science ®Google Scholar
• Terry R D, Davies P. Some morphologic and biochemical aspects of Alzheimer's Disease. Aging of the Brain, D Samuel, S Algeri, S Gershon, V E Grimm, G Toffano. Raven Press, New York 1983; Vol 22: 47–59
   Google Scholar
• Carlsson A, Adolfsson R, Aquilonius S M, et al. Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism. Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects, M Goldstein, D B Calne, A Lieberman, M O Thorner. Raven Press, New York 1980; 295–314
   Google Scholar
• Toralinson B E, Blessed G, Roth M L. Observations on the brains of demented old people. J Neurol Sci 1970; 11: 205–242
   PubMed Web of Science ®Google Scholar
• Yamamoto R, Ilirano A. Nucleus raphe dorsalis in Alzheimer's disease: Neurofibrillary tangles and loss of large cortical neurons. Ann Neurol 1985; 17: 573–577
   PubMedGoogle Scholar
• Gottfries O G, Adolfsson R, Aquilonius S M. Biochemical changes in dementia disorders of Alzheimer's type (AD/SAT). Neurobiol Aging 1983; 4: 261–271
   PubMed Web of Science ®Google Scholar
• Rossor M NL. Neurotransmitters in CNS disease Dementia. Lancet 1982; 2: 200–204
   PubMedGoogle Scholar
• Iwangoff P, Armbuster R, Enz A, Meier-Ruge W, Sandoz P. Glycolytic enzymes from human autoptic brain cortex: Normally aged and demented cases. Biochemistry of Dementia, P J Roberts. John Wiley & Sons, London and New York 1980; 258–262
   Google Scholar
• Iwangoff P, Reichlmeier K, Enz A, Meier-Ruge W. Neurochemical findings in physiological aging of the brain. Interdiscipl Topics Gerontol 1979; 15: 13–33
   Google Scholar
• Perry I K, Perry R H. The cholinergic system in Alzheimer's disease. Biochemistry of Dementia, P J Roberts. John Wiley & Sons, London and New York 1980; 135–183
   Google Scholar
• Bartus R T, Dean R L, Beer B, Lippa A S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–417
   PubMed Web of Science ®Google Scholar
• Brinkman D S, Gershon S. Measurement of cholinergic drug effects on memory in Alzheimer's disease. Neurobiol Aging 1983; 4: 261–271
   PubMed Web of Science ®Google Scholar
• Christie J E, Shering A, Ferguson J, Glen A IM. Physostigmine and arecholine: effects of intravenous infustion in Alzxheimer presenile dementia. Br J Psychiatri 1981; 138: 46–50
   PubMed Web of Science ®Google Scholar
• Wettstein A, Spiegel R, Koppel-Hefti A. Therapeutic trial with the muscarinic agonist RS-86 in patients with senile dementia of Alzheimer type. Presented at the Collegium Internationale Neuro-Psychopharmacologicum Congress, FlorenceItaly, June, 18–231983, 983
   Google Scholar
• Bruno G, Mohr R, Gillespie M M, Fedio P., Chase T N. RS-86 therapy of Alzheimer's disease. Neurology 1985; 35(1)265, (suppl)
   Google Scholar
• Zornetzer S G. Nmeurotransmitter modulation andmemory: A new neuropharmacological phrenology. Psychopharmacology: A Generation of Progress, M A Lipton, A De Mascio, K F Killam. Raven Press, New York 1978; 637–649
   Google Scholar
• Jellinger K, Flament H, Riederer P, Schmid H, Ambrogi L. Levodopa in the treatment of (pre)senile dementia. Mech Aging Dev 1980; 14: 253–264
   PubMed Web of Science ®Google Scholar
• Ferris S H, Reisberg B, Friedman E. “Combination choline-piracetam treatment of senile dementia.”. Psychopharmacol Bull 1982; 18: 94
   Google Scholar
• Cutler N R, Haxby J, Kay A D, et al. Evaluation of zimelidine in Alzheimer's disease: Cognitive and biochemical measures. Arch Neurol 1985; 42: 744–748
   PubMed Web of Science ®Google Scholar
• Davies P, Katzman R, Terry R D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer's senile dementia. Nature 1980; 288: 179–280
   PubMed Web of Science ®Google Scholar
• Rossnor M N, Emson P C, Mountjoy C Q, Roth M, Iverson L L. Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alsheimer's type. Neurosci Lett 1980; 20: 373–377
   PubMed Web of Science ®Google Scholar
• Beal M G, Mazurek M F, Tran V T, Chattha G, Bird E D, Martia J B. Reduced numbers of somatostatin receptors in cerebral cortex in Alzheimer's disease. Science 1985; 229: 289–291
   PubMed Web of Science ®Google Scholar
• Delf J R, Zhy C, Dichter M A. Co-existence of acetylcholinesterase and somatostatin-immunoreactivity in neurons cultured from rat cerebrum. Science 1984; 223: 61–63
   PubMed Web of Science ®Google Scholar
• Ferris S H. Neuropeptides in the treatment of Alzheimer's disease. Alzheimer's Disease, B Reisberg. The Free Press, New York 1983; 369–373
   Google Scholar
• Veber D F, Saperstein R, Nutt R F, et al. A super active cyclic hexapeptide analog of somatostatin. Life Sci 1984; 314: 1371–1378
   Google Scholar
• Folstein M F, Folstein S E, McHugh P R. Mini-Mental State, a practical method for grading the cognitive state of patients for the clinical. J Psychiatr Res 1975; 12: 189–198
   PubMed Web of Science ®Google Scholar
• Cutler N R, Haxby J V, Narang P K, May C, Burg C, Reines S A. “Evaluation of an analogue of somatostatin (L-363,586) in Alzheimer's disease.”. N Engl J Med 1985; 312: 725
   PubMed Web of Science ®Google Scholar
• Kastin A J, Olson G A, Sandman C A. Possible role of peptides in senile dementia. Strategies for the Development of an Effective Treatment for Senile Dementia, T Crook, S Gerson. Mark Powler Associates, New Canaan, CT 1981; 139–152
   Google Scholar
• Reisberg B, Ferris S H, Anand R. Effects of naloxone in senile dementia: a double blind trial. N Engl J Med 1983; 308: 721–722
   PubMed Web of Science ®Google Scholar
• Glass J P, Reding M J, Drachman E. “Cholinesterase inhibitors and opiate antagonists in patients with Alzheimer's disease.”. N Eng J Med 1983; 309: 566
   Google Scholar
• Bjorklund A, Gage F H, Schmidt R H, Stenevi U, Dunnet S B. Intracerebral grafting of neuronal cell suspensions VII. Recovery of choline acetyltransferase activity and acetylcholin synthesis in the denervated hippocampus reinnervated by septal suspension implants. Acta Physiol Scand 1983; 59–66, (suppl 522)
   Google Scholar
• Rossnor M N, Iverson L L, Reynolds G P, Mountjoy C Q, Roth M. Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J 1984; 288: 961–964
   PubMed Web of Science ®Google Scholar
• Blessed G, Tomlinson B E, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: L797–811
   PubMed Web of Science ®Google Scholar
• Mattis S. Mental status examination for organic mental syndrome in the elderly patient. Geriatric Psychiatri: A Handbook for Psychiatrists and Primary Care Physicians, L Bellak, R Katasu. GruneS Stratton, New York 1976; Vol 7: 77–121
   Google Scholar
• Thai L J, Fuld P A, Masur D M, Sharpless N S. Oral psysostigmine and lecithin improve memory in Alzheimer's disease. Ann Neurol 1983; 13: 491–195
   PubMed Web of Science ®Google Scholar
• Wettstein A. No effect from double-blind trial of psysostigmine and lecithin in Alzheimer's disease. Ann Neurol 1983; 13: 210–212
   PubMed Web of Science ®Google Scholar
• Wechsler D. A standardized memory scale for clinical use. J Psychol 1945; 19: 87–95
   Web of Science ®Google Scholar
• Benton A C. The Revised Visual Retention Test. Psychological Corporation, New York 1974
   Google Scholar
• Benson D R. Aphasia. Clinical Neuropsychology, E M Heilman, E Valenstein. Oxford University Press, New York 1979; 22–58
   Google Scholar